Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Expands By 89.2%

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 679,358 shares, an increase of 89.2% from the January 29th total of 358,994 shares. Approximately 19.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 895,841 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily trading volume, of 895,841 shares, the days-to-cover ratio is currently 0.8 days. Approximately 19.5% of the shares of the stock are short sold.

Strata Skin Sciences Stock Down 3.5%

SSKN opened at $0.25 on Friday. Strata Skin Sciences has a 1 year low of $0.12 and a 1 year high of $3.86. The firm has a 50 day moving average price of $1.02 and a 200 day moving average price of $1.47. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95. The company has a market cap of $1.47 million, a PE ratio of -0.09 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Strata Skin Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Strata Skin Sciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Strata Skin Sciences

A hedge fund recently bought a new stake in Strata Skin Sciences stock. Susquehanna International Group LLP purchased a new stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.24% of Strata Skin Sciences at the end of the most recent quarter. Institutional investors and hedge funds own 32.43% of the company’s stock.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.